Ethical and human subject burdens of trials conducted to evaluate biosimilars
Jennifer A. Ohn, Preston J. Atteberry, Mark R. Trusheim, Peter B. Bach
doi: https://doi.org/10.1101/2021.03.05.21252938
Jennifer A. Ohn
1Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY
MPHPreston J. Atteberry
2Department of Medicine, NewYork Presbyterian Hospital, New York, NY
MDMark R. Trusheim
3Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, MA
MScPeter B. Bach
1Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY
MD, MAPP
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable request.
Posted March 09, 2021.
Ethical and human subject burdens of trials conducted to evaluate biosimilars
Jennifer A. Ohn, Preston J. Atteberry, Mark R. Trusheim, Peter B. Bach
medRxiv 2021.03.05.21252938; doi: https://doi.org/10.1101/2021.03.05.21252938
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)